Identification of a Plasma Proteomic Signature for Lung Cancer
Blood samples are obtained from those patients undergoing procedures to determine if a lung
nodule is benign or cancerous. The data from the study will not be used to guide or
influence the treatment of the patients enrolled in this study. There is no change from the
normal standard of care that patients receive.
Observational Model: Cohort, Time Perspective: Prospective
Incidence rate of Non-Small Cell Lung Cancer
The incidence rate of non-small cell lung cancer in the study population will be correlated to the predictive value of the Sponsor's blood test.
24 months after enrollment
Ken Fang, MD
Integrated Diagnostics, Inc.
United States: Quorum Review IRB
|Mayo Clinic||Rochester, Minnesota 55905|
|Geisinger Medical Center||Danville, Pennsylvania 17822-0001|
|Henry Ford Hospital||Detroit, Michigan 48202|
|Greater Baltimore Medical Center||Baltimore, Maryland 21204|
|University of Cincinnati||Cincinnati, Ohio 45267-0502|
|Group Health Research Institute||Seattle, Washington 98101|
|Kaiser Permanente Northern California||Oakland, California 94612|
|Intermountain Healthcare||Salt Lake City, Utah 84103|
|North East Alabama Regional Medical Center||Anniston, Georgia 36207|
|Lahey Hospital & Medical Center||Burlington, Massachusetts 01805|
|Cardiopulmonary Research Science and Technology Institute||Dallas, Texas 75230|